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Background  
There is limited evidence to support very early intensive aphasia rehabilitation as a best-practice 
standard in stroke care. VERSE is a randomised, open-label, blinded endpoint evaluation trial designed 
to determine whether two different types of intensive aphasia therapy, provided for 20 sessions, 
beginning within 14 days of acute stroke, provides greater efficacy and cost-effectiveness than usual 
care. 
Methods  
246 participants with acute post-stroke aphasia who meet the selection criteria are required. Participants 
are stratified by aphasia severity and randomised to receive usual care (usual ward based aphasia 
therapy), usual care-plus (usual ward based therapy provided daily) or VERSE therapy (a prescribed 
aphasia therapy provided daily). The primary outcome is the Aphasia Quotient of the Western Aphasia 
Battery at three months. Secondary outcomes include resource use, quality-of-life and depression 
measures. 
Results 
14 sites are involved in the trial with 11 sites actively recruiting to date. 3206 people with confirmed 
stroke have been identified since July 2014. 784 patients had aphasia (24%) and 157 (20%) were trial 
eligible. Of those, 67 (42%) have been recruited (September 2015). The top two reasons for non-
enrolment include: Out of area rehabilitation services (32%) and participant refusal (20%). 
Discussion 
The post-stroke aphasia rate is lower than predicted.  Our recruitment rate is higher than anticipated for 
this population. A new multi-site network has been built for this trial, which has slowed start up. When 
complete, this trial will provide Level 1 evidence to support clinical practice guidelines. Site recruitment 
is still open. 
 
 
 
 
 
